An updated radiosynthesis of [18F]AV1451 for tau PET imaging

被引：17
作者：
Mossine A.V. [1 ]
Brooks A.F. [1 ]
Henderson B.D. [1 ]
Hockley B.G. [1 ]
Frey K.A. [1 ]
Scott P.J.H. [1 ]
机构：
[1] Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, 48109, MI
来源：
EJNMMI Radiopharmacy and Chemistry | / 2卷 / 1期
关键词：
Automated radiosynthesis; Brain PET; Flortaucipir F18; Fluorine-18; radiochemistry; Tau imaging; [!sup]18[!/sup]F]T807;
D O I：
10.1186/s41181-017-0027-7
中图分类号：
学科分类号：
摘要：
Background: [18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide doses suitable for use in clinical imaging studies. To address this issue, we have modified the synthesis of [18F]AV1451 to use only 0.5 mg precursor, optimized the Boc-deprotection step and developed a simplified method for HPLC purification of the radiotracer. Results: An optimized [18F]AV1451 synthesis using a TRACERLab FXFN module led to high radiochemical yield (202 ± 57 mCi per synthesis) and doses with excellent radiochemical purity (98 ± 1%) and good specific activity (2521 ± 623 Ci/mmol). Conclusion: An updated and operationally simple synthesis of [18F]AV1451 has been developed that is fully automated and prepares radiotracer doses suitable for use in clinical tau PET studies. © 2017, The Author(s).
引用
收藏
相关论文
共 42 条
  • [21] Jack C.R., Wiste H.J., Weigand S.D., Therneau T.M., Lowe V.J., Knopman D.S., Gunter J.L., Senjem M.L., Jones D.T., Kantarci K., Machulda M.M., Mielke M.M., Roberts R.O., Vemuri P., Reyes D.A., Petersen R.C., Defining imaging biomarker cut points for brain aging and Alzheimer’s disease, Alzheimers Dement, 13, 3, pp. 205-216, (2017)
  • [22] Kolb H.C., Andres J.I., Tau Positron Emission Tomography Imaging, Cold Spring Harbor Perspectives in Biology, 9, (2017)
  • [23] Maran F., Celadon D., Severin M.G., Vianello E., Electrochemical Determination of the pKa of Weak Acids in N,N-Dimethylformamide, J Am Chem Soc, 113, 24, pp. 9320-9329, (1991)
  • [24] Marquie M., Normandin M.D., Meltzer A.C., Siao Tick Chong M., Andrea N.V., Anton-Fernandez A., Klunk W.E., Mathis C.A., Ikonomovic M.D., Debnath M., Bien E.A., Vanderburg C.R., Costantino I., Makaretz S., DeVos S.L., Oakley D.H., Gomperts S.N., Growdon J.H., Domoto-Reilly K., Lucente D., Dickerson B.C., Frosch M.P., Hyman B.T., Johnson K.A., Gomez-Isla T., Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann, Neurol, 81, 1, pp. 117-128, (2017)
  • [25] McMillan C.T., Irwin D.J., Nasrallah I., Phillips J.S., Spindler M., Rascovsky K., Ternes K., Jester C., Wolk D.A., Kwong L.K., Lee V.M., Lee E.B., Trojanowski J.Q., Grossman M., Multimodal evaluation demonstrates in vivo <sup>18</sup>F‐AV‐1451 uptake in autopsy‐confirmed corticobasal degeneration, Acta Neuropathol, 132, 6, pp. 935-937, (2016)
  • [26] Biomed. Res. Int, (2016)
  • [27] Passamonti L., Vazquez Rodriguez P., Hong Y.T., Allinson K.S., Williamson D., Borchert R.J., Sami S., Cope T.E., Bevan-Jones W.R., Jones P.S., Arnold R., Surendranathan A., Mak E., Su L., Fryer T.D., Aigbirhio F.I., O'Brien J.T., Rowe J.B., F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy, Brain, 140, 3, pp. 781-791, (2017)
  • [28] Mol. Neurodegener, (2017)
  • [29] Schwarz A.J., Yu P., Miller B.B., Shcherbinin S., Dickson J., Navitsky M., Joshi A.D., Devous M.D., Mintun M.S., Regional profiles of the candidate tau PET ligand 18 F-AV-1451 recapitulate key features of Braak histopathological stages, Brain, 139, pp. 1539-1550, (2016)
  • [30] Scott P.J.H., Kilbourn M.R., Determination of residual kryptofix 2.2.2 levels in [<sup>18</sup>F]-labeled radiopharmaceuticals for human use, Appl Radiat Isot, 65, pp. 1359-1362, (2007)
12345